Please login to the form below

Not currently logged in
Email:
Password:

Wilson disease

This page shows the latest Wilson disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer goes big on gene therapy with $500m facility spend

Pfizer goes big on gene therapy with $500m facility spend

It also took a 15% stake in  Vivet Therapeutics and its lead programme for Wilson disease, a devastating rare, chronic and potentially life-threatening liver disorder.

Latest news

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    Pfizer has been steadily adding to its rare disease assets via a series of takeovers and alliances to complement its own R&D in this area. ... TA-46 will add to other pipeline candidates including Sangamo-partnered haemophilia A gene therapy SB-525,

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    Vivet Therapeutics’ lead candidate is VTX-801, a gene therapy for Wilson disease, a devastating rare, chronic, and potentially life-threatening liver disorder. ... Pfizer will work closely with Vivet to help it develop its expertise in liver-directed

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    Alexion has agreed a $1.2bn takeover of US biotech Syntimmune that will add another clinical-stage rare disease drug to its R&D pipeline. ... $855m, adding orally-active copper binder WTX-101 in phase 3 testing for genetic disorder Wilson’s disease.

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    Also acquires the Swedish group’s lead product for Wilson’s disease. Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a ... Sweden-based Wilson’s lead product is WTX101, currently in phase III development

  • mRNA - message received mRNA - message received

    Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Moreover, broadly-applicable and generic RNA manufacturing techniques are compatible with the rapid

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...